Therapeutic Antibodies

T cells
#Antibodies #Covid-19 #Immunology / Virology & Vaccines #Online focus #Vaccines

T Cells recognise recent SARS-CoV-2 variants

When variants of SARS-CoV-2 emerged in late 2020, concern arose that they might elude protective immune responses generated by prior infection or vaccination, potentially making re-infection more likely or vaccination less effective. To investigate this possibility, researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the… Read More

#Covid-19 #News

#Antibodies #Covid-19 #Online focus

Putting function first to find antibodies against difficult target

Three case studies from Berkeley Lights The Covid-19 pandemic has illuminated how a coordinated response to infectious diseases can result in the development and commercialisation of novel vaccines and therapies at record pace. Berkeley Lights has established multiple partnerships worldwide to provide access to its platform to rapidly accelerate the… Read More

#Covid-19 #News

#Antibodies #Biologics #Covid-19 #Drug development #Drug discovery #Online focus

IONTAS has identified novel SARS-CoV-2 neutralising antibodies

IONTAS and FairJourney Biologics have identified neutralising antibodies, which bind to multiple emerging SARS-CoV-2 variants. The results, generated from a combination of phage display technology and B-cell receptor repertoire sequencing of hospitalised COVID-19 patients, identified potent neutralising antibodies with distinct mechanisms of action. Based on this approach, the company has… Read More

#News

#Antibodies #Drug development #Drug discovery #Huntington's disease

Collaboration to develop landmark novel antibody therapy for Huntington’s

Alchemab, a biotech company harnessing the power of naturally protective antibodies, has been awarded a UK Biomedical Catalyst early award grant from Innovate UK to support its collaboration with Medicines Discovery Catapult and the development of a novel disease-modifying antibody therapy for Huntington’s disease. Using its novel approach, Alchemab has… Read More

#News

#Antibodies #Biologics #Biologics / Biotechnology #Cell therapy

IONTAs and FairJourney antibody agreement with Quell Therapeutics

IONTAS and FairJourney Biologics (FJB) have entered into an agreement with Quell Therapeutics regarding IONTAS / FJB’s proprietary libraries and technology platforms. A diverse panel of novel target binders from IONTAS and FairJourney Biologics (FJB) will be used to identify antibodies to advance Quell’s engineered Treg cell therapy pipeline. Quell… Read More

#News #Trending News

#Antibodies #Nanobodies

ChromoTek and Absolute Antibody collaborate on recombinant antibodies

ChromoTek, part of Proteintech specialising in nanobody-based reagents, and Absolute Antibody, provider of recombinant antibody technology, have announced a partnership to offer recombinant engineered antibodies to scientists worldwide. The chimeric antibodies were originally derived from alpaca nanobodies and engineered onto mouse and rabbit Fc domains to open up new research… Read More

#News

#Antibodies #Biotechnology

Exclusive: The man behind the next generation antibody discovery platform

Last year IONTAS, a biotechnology company focused on antibody discovery and development, entered into a licensing agreement with Bristol Myers Squibb for its proprietary mammalian display. John McCafferty, nuclease directed mammalian display inventor and co-inventor of antibody phage display, told Lu Rahman about this breakthrough work. The company operates as… Read More

#Exclusive Content #News #Opinion

#Biologics #Cancer immunotherapy #Oncology

Samsung Biologics obtains cancer immunotherapy IND approval from FDA

Samsung Biologics has obtained Investigational New Drug (IND) clearance from the FDA for its client to begin clinical trials on a cancer immunotherapy. In late 2018, National OncoVenture (NOV), a government-funded virtual oncology drug development program in Korea, approached Samsung Biologics for the development of EU101(NOV1801), an anti-4-1BB therapeutic monoclonal… Read More

#Cancer Research #News

#Antibody response #Biologics #Drug targets #Novel therapeutics #RNA #siRNA

Sitting down with…Michael Smyth, Galapagos UK

Michael Smyth is Medical Director at Galapagos UK, responsible for launching innovative therapies in the UK to help change the course of inflammatory disease for patients. Having studied medicine at Liverpool University, one of his personal missions is lifelong learning which is reflected in his role to strive for new treatment… Read More

#Editor's Choice #News #Opinion

#Antibodies #Drug discovery

Flow Eighteen38, a new protein sciences service

FairJourney Biologics (FJB) and IONTAS, specialists in the discovery and optimisation of antibodies, have launched of a new protein sciences division, Flow Eighteen38. The new business unit has been introduced to accelerate customer antibody research projects, by delivering reagents, purified proteins, and characterisation data on antibody panels and leads. As… Read More

#News

#Antibodies

A rapid method to quantitatively screen bispecific antibody using protein A and His1K biosensors

Recent biotechnological advances have fueled development bispecific antibodies (bsAbs) in the last 10 years. However, the functional analysis of bsAbs during bioprocessing adds a challenge for scientists given the wide array of bsAbs populated by many different species, comprising many different formats, and that traditional SPR and ELISA methods for… Read More

#Resources

#Antibodies #Assay development & optimisation #Bispecific therapeutics

Fast way to screen bispecific antibodies using protein A and His1K biosensors

Recent biotechnological advances have fuelled development bispecific antibodies (bsAbs) in the last 10 years. However, the functional analysis of bsAbs during bioprocessing adds a challenge for scientists given the array of bsAbs populated by many different species, comprising many different formats, and that traditional SPR and ELISA methods for bsAbs… Read More

#News

#Biologics #Cell therapy

Solentim new standards in productivity with antibodies workflow solutions

Solentim, expert in cell therapy workflows enabling the creation, isolation and characterisation of high value cells, has launched two solutions to enhance the development of therapeutic antibodies. Icon is a benchtop system for the rapid stratification of high productivity clones and Studius is a proprietary software platform that delivers data… Read More

#News

#Antibodies #Covid-19 #Drug discovery

How to achieve accurate affinity profiling of a SARS-CoV-2 antibody in serum

Measuring antibody affinity under physiologically relevant conditions in complex mixtures like serum remains challenging but is critically important to furthering our understanding of the immune response and protection window in patients and vaccinated individuals. Fluidic Analytics’ application note explains why current technologies provide only an incomplete understanding of the… Read More

#Covid-19 #News